The current firestorm over high drug prices didn’t start with the May 2019 approval of Novartis’s onasemnogene abeparvovec-xioi‎ (Zolgensma), a gene therapy for spinal muscular atrophy and the “world’s most expensive drug” at $2.1 million per treated patient, but this development is certainly fanning the flames.

Continue reading on Health Affairs.